Class / Patent application number | Description | Number of patent applications / Date published |
514800800 | Bone morphogenic protein (BMP) or derivative | 75 |
20100273706 | Injectable Calcium Phosphate Solid Rods and Pastes for Delivery of Osteogenic Proteins - Osteogenic proteins are delivered via an injectable solid rod or hardenable paste. The formulation comprises a calcium phosphate material, an osteogenic protein, and optional additives and active ingredients such as a bone resorption inhibitor. Methods of making injectable pharmaceutical compositions and methods of using the osteogenic compositions to treat bone defects are also disclosed. | 10-28-2010 |
20100292146 | COMPOSITE BONE REPAIR MATERIAL - The present invention relates to a sliceable composite bone repair material comprising a porous block-shaped ceramic scaffold and a stabilizing polymer disposed therein. Said ceramic scaffold is a synthetic ceramic material or a naturally-derived material. Additionally said scaffold comprises interconnected macropores. | 11-18-2010 |
20100305035 | Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative - The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above. | 12-02-2010 |
20110021427 | BIPHASIC CALCIUM PHOSPHATE CEMENT FOR DRUG DELIVERY - This invention relates to biomineral-based cements incorporating biopolymer carriers for the site specific introduction of natural or synthetic compounds that influence bone repair and/or patient recovery. The invention further relates to methods for producing such biphasic calcium phosphate cements for drug delivery. | 01-27-2011 |
20110028393 | FLOWABLE PASTE AND PUTTY BONE VOID FILLER - The present invention provides a composition that may be used as an implant or a bone graft substitute or extender for filling voids and/or promoting fusion of osseous tissues. The implant may comprise ceramic granules such as calcium phosphate granules and one or more polysaccharide excipients, and may be in the form of a putty or flowable paste. Optionally, the implant may also comprise a growth factor such as a bone morphogenetic protein. | 02-03-2011 |
20110039773 | BMP Mutants with Decreased Susceptibility to Noggin - The present invention provides modified, highly potent bone morphogenetic proteins. In particular, the present invention relates to the observation that BMP-6 and BMP-9 are less susceptible to inhibition by Noggin that are other members of the BMP subfamily of proteins. The present invention features chimeric bone morphogenetic proteins in which the middle portion of BMP-6 or BMP-9 replaces the middle portion of another BMP subfamily protein to cause resistance to inhibition by Noggin or other Noggin-like antagonists. Other embodiments of modified BMPs, compositions and methods of use are also included. | 02-17-2011 |
20110082081 | COMPOSITIONS AND METHODS FOR REPAIR OF TISSUES - Biomaterials providing sustained release of growth factor for repair of tissues such as bone and cartilage are disclosed. The biomaterials comprise a proteoglycan derived from domain I of perlecan and a growth factor, and, optionally, collagen. | 04-07-2011 |
20110178011 | Polysaccharide/BMP complexes which are soluble at physiological pH - A complex of a polysaccharide and recombinant human BMP-2 and BMP-7, soluble at physiological pH, wherein the polysaccharide/BMP mass ratio is less than 15, the polysaccharide being selected from the group of polysaccharides having carboxyl functional groups, at least one of which is substituted with at least one hydrophobic radical. | 07-21-2011 |
20110224138 | METHODS FOR TREATING PAIN INDUCED BY INJURIES AND DISEASES OF AN ARTICULAR JOINT - Described herein are methods for using bone morphogenetic proteins (BMPs), such as OP-1 (also known as BMP-7), to treat pain caused by osteoarthritis. The methods involve administering to a patient suffering from pain caused by osteoarthritis a BMP, for example, intraarticularly by injection directly into the joint afflicted with osteoarthritis. The methods of the invention provide long-term pain relief to sufferers of osteoarthritis and can improve the functionality of the joint to which the BMP is administered. | 09-15-2011 |
20110230406 | AFFINITY PEPTIDES TOWARD BMP-2 - We have disclosed affinity peptides toward BMP-2. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for BMP-2. | 09-22-2011 |
20110237506 | PROTEIN STABILIZATION FORMULATIONS - The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants. | 09-29-2011 |
20110257093 | THERAPIES FOR ACUTE RENAL FAILURE - The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-β superfamily of proteins. | 10-20-2011 |
20110257094 | ANTI PERIODONTITIS-CAUSING MICROORGANISM AGENT AND MEDICAL OR DENTAL MATERIALS USING THE SAME - A medical or dental material can be prepared by using, as an active ingredient, at least one of a protamine, and derivatives thereof and hydrolysates thereof, or a complex of at least one of a protamine, and derivatives thereof and hydrolysates thereof with an anionic high molecular weight compound. As a result, an antibacterial agent against periodontal disease-causing bacteria can be provided, which is highly safe without concern of a side effect. A medical or dental material can be also provided, which exhibits antimicrobial activity on periodontal disease-causing bacteria and additionally has insolubility in water and good formability. | 10-20-2011 |
20110263499 | IFBM'S TO PROMOTE THE SPECIFIC ATTACHMENT OF TARGET ANALYTES TO THE SURFACE OF ORTHOPEDIC IMPLANTS - The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant. | 10-27-2011 |
20110319328 | BONE MORPHOGENETIC PROTEIN COMPOSITIONS - The present invention relates to compositions of bone morphogenetic proteins, particularly solid and liquid formulations of such proteins comprising one or more stabilizing excipients. The invention further provides methods of producing the compositions, kits comprising the compositions and methods of using the compositions in the treatment of diseases of skeletal and non-skeletal tissues. | 12-29-2011 |
20120004170 | Formulation Comprising Bioactive Agents And Method Of Using Same - Disclosed are methods of making bioactive BMP-2 microparticles and methods of using the microparticles. | 01-05-2012 |
20120004171 | NOVEL THERAPIES FOR CHRONIC RENAL FAILURE - The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-β superfamily of proteins. | 01-05-2012 |
20120046227 | DESIGNER OSTEOGENIC PROTEINS - The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics. | 02-23-2012 |
20120058944 | BONE MORPHOGENETIC PROTEIN 2 (BMP2) VARIANTS WITH REDUCED BMP ANTAGONIST SENSITIVITY - The present invention is directed to an isolated peptide comprising or consisting of an amino acid sequence with an amino acid identity of at least 90% compared to mature human BMP2 with SEQ ID No. 1, characterized in that said amino acid sequence comprises at least two amino acid substitutions characterized in that a first amino acid substitution occurs at a position corresponding to N59, S88, E94, V99, K101 and/or N102 of SEQ ID No. 1 and to uses thereof. | 03-08-2012 |
20120077743 | METHODS OF TREATING CARTILAGE DEFECTS - The present invention provides methods of repairing and regenerating cartilage tissue by administering into the cartilage or the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein. | 03-29-2012 |
20120122778 | Modified TGF-beta superfamily protein - The invention provides modified TGF-β family proteins having altered biological or biochemical properties, and methods for making them. Specific modified protein constructs include TGF-β family member proteins that have N-terminal truncations, “latent” proteins, fusion proteins and heterodimers. | 05-17-2012 |
20120135927 | BONE MORPHOGENETIC PROTEINS FOR THE TREATMENT OF INSULIN RESISTANCE - The present disclosure relates to compositions and methods for treating insulin resistance and/or obesity in a cell and/or a subject. | 05-31-2012 |
20120165257 | COMPOSITIONS AND METHODS FOR TREATING JOINTS - Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression. | 06-28-2012 |
20120178684 | Surgical Calcium Phosphate Citrate-Containing Cement and Method of Manufacturing the Same - The present invention discloses a surgical cement and a manufacturing method thereof. The surgical cement comprises a cementing component selected form the group of a basic calcium phosphate consisting of tetracalcium phosphate, alpha-tricalcium phosphate, decomposed hydroxyapatite, or a combination thereof; a setting reagent selected form the group of an acidic calcium citrate consisting of monocalcium citrate, dicalcium citrate, or a combination thereof; and water; wherein a weight ratio of the cementing component and the setting reagent ranges from about 1:1 to about 8:1. The surgical cement is bioresorbable and bioactive and is useful in orthopedic, maxillofacial and dental applications. In addition, the surgical cement of this invention has a good flow character and a relatively short setting time. | 07-12-2012 |
20120184490 | ENHANCEMENT OF BMP RETENTION - The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical co | 07-19-2012 |
20120202741 | DELIVERY OF BMP-7 AND METHODS OF USE THEREOF - The present invention generally relates to delivery of BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist and methods of use thereof. In some embodiments, methods and devices are provided for delivery of BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist to a patient. In some cases, the BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist may be released in controlled fashion from a device in fluid communication with a patient. In some embodiments, the BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist may be expressed by cells within a device. In other embodiments, methods are provided for improving the function of devices containing renal proximal tubule cells. For example, in some embodiments, exposure of renal proximal tubule cells to BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist may be used to inhibit disruption of cell layers comprising renal proximal tubule cells. In another embodiment, exposure of renal proximal tubule cells to BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist may be used to inhibit trans- and de-differentiation of renal proximal tubule cells. In another embodiment, exposure of renal proximal tubule cells to BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist may be used to improve renal proximal tubule cell functions. | 08-09-2012 |
20120208753 | Composition and Method for the Treatment or Prevention of Spinal Disorders III - The present invention relates to compositions comprising a modulator of GDF-6 signaling for the prevention of and/or treatment of a spinal disorder and/or spinal pain, eg., caused by and/or associated with intervertebral disc degeneration and methods of treatment of a spinal disorder and/or spinal pain comprising administering a modulator of GDF-6 signaling, or a composition comprising thereof. | 08-16-2012 |
20120258917 | Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease - The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent. | 10-11-2012 |
20120277152 | COMPRESSED HIGH DENSITY FIBROUS POLYMERS SUITABLE FOR IMPLANT - An embodiment of the present invention may be made by the following steps: providing a mixture comprising a plurality of fibers, a lubricant, and a suspension fluid, with the suspension fluid filling a void space between said fibers and subjecting said mixture to at least one compressive force. The compressive force causes the migration and alignment of said fibers; and may remove substantially all of the suspension fluid from said mixture. The mixture may further comprise a biologically active agent, or a reinforcing agent. | 11-01-2012 |
20120309680 | Functionalized oligosaccharides - The invention relates to an oligodextran, chosen from dextrans whose average degree of polymerization is less than 10, modified by at least one substituent of general formula I: | 12-06-2012 |
20130045919 | Sustained-Release Formulations Comprising Crystals, Macromolecular Gels, and Particulate Suspensions of Biologic Agents - The present invention is directed to sustained release formulations of biologic agents which permit persistent bioavailability. Preferred biologic agents include bone morphogenetic proteins. Diseases susceptible to amelioration and/or treatment with the formulations of the present invention include skeletal tissue diseases such as, but not limited to, osteoarthritis and other osteochondral diseases. The sustained release formulations of the present invention are especially suitable for treatment of minimally-vascularized or non-vascularized tissue sites such as, but not limited to, intra joint, interarticular, or intraminiscal sites. | 02-21-2013 |
20130045920 | Flowable Ceramic Putty - The invention relates to a composition comprising an aqueous admixture of ceramic particles, polysaccharide, a therapeutic agent and, optionally, a polymer, and methods of using the same. The present invention provides a flowable bone void filler for use in medical situations where bone regeneration is desired. In an exemplary embodiment the bone void filler comprises a polysaccharide, a ceramic material and a polymer that exhibits thermosetting properties such that it exists as a viscous liquid at room temperatures and as a gel at about body temperature. In another exemplary embodiment the bone void filler comprises a polysaccharide, a ceramic material, a polymer that exhibits thermosetting properties such that it exists as a viscous liquid at room temperature and as a gel at about body temperatures, and a therapeutic agent. | 02-21-2013 |
20130090290 | BMP-2 Peptides and Methods of Use - The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. | 04-11-2013 |
20130137634 | COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO - The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. | 05-30-2013 |
20130143811 | Tumor Suppression Compositions - Provided herein is tumor suppression composition and methods of making and using the same. | 06-06-2013 |
20130150295 | Sustained-Release Formulations Comprising Crystals, Macromolecular Gels, and Particulate Suspensions of Biologic Agents - The present invention is directed to sustained release formulations of biologic agents which permit persistent bioavailability. Preferred biologic agents include bone morphogenetic proteins. Diseases susceptible to amelioration and/or treatment with the formulations of the present invention include skeletal tissue diseases such as, but not limited to, osteoarthritis and other osteochondral diseases. The sustained release formulations of the present invention are especially suitable for treatment of minimally-vascularized or non-vascularized tissue sites such as, but not limited to, intrajoint, interarticular, or intraminiscal sites. | 06-13-2013 |
20130157947 | COMPOUNDS FOR STEM CELL DIFFERENTIATION - Small molecule compounds and methods for stem cell differentiation are provided herein. An example of a class of compounds that may be used to practice the methods disclosed herein is represented by enantiomerically pure isomers of compounds of Formula I: | 06-20-2013 |
20130172254 | Buffers for Controlling the pH of Bone Morphogenetic Proteins - The present invention provides formulations of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins that are pH stabilized. In particular, the present invention relates to the observation that certain buffers enhance the stability of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins. In particular, disclosed herein are liquid and lyophilized formulations prepared with a glycylglycine and tartaric acid buffers to stabilize the pH of the formulation. | 07-04-2013 |
20130172255 | COMPOSITIONS AND METHODS FOR TREATING JOINTS - Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression. | 07-04-2013 |
20130184208 | BMP Mutants with Decreased Susceptibility to Noggin - The present invention provides modified, highly potent bone morphogenetic proteins. In particular, the present invention relates to the observation that BMP-6 and BMP-9 are less susceptible to inhibition by Noggin that are other members of the BMP subfamily of proteins. The present invention features chimeric bone morphogenetic proteins in which the middle portion of BMP-6 or BMP-9 replaces the middle portion of another BMP subfamily protein to cause resistance to inhibition by Noggin or other Noggin-like antagonists. Other embodiments of modified BMPs, compositions and methods of use are also included. | 07-18-2013 |
20130184209 | PROTEIN STABILIZATION FORMULATIONS - The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants. | 07-18-2013 |
20130190236 | BMP-7 Variants with Reduced Immunogenicity - The invention is directed to bone morphogenetic proteins that have reduced immunogenicity. In particular, the invention is directed to human BMP-7 that has been modified to reduce immunogenicity through alteration of the amino acid sequence of wild-type BMP-7. | 07-25-2013 |
20130196909 | BMP-7 Peptides and Methods of Use - The invention relates to truncated growth factors and variants thereof. The invention also relate to methods of making and using the truncated growth factors. | 08-01-2013 |
20130196910 | BMP-4 PEPTIDES AND METHODS OF USE - The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. | 08-01-2013 |
20130231284 | METHODS OF TREATING CARTILAGE DEFECTS - The present invention provides methods of repairing and regenerating cartilage tissue by administering into the cartilage or the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein. | 09-05-2013 |
20130281371 | METHODS AND COMPOSITIONS FOR INCREASING RED BLOOD CELLS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 10-24-2013 |
20130288966 | Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease - The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent. | 10-31-2013 |
20130303449 | SURGICAL APPLICATIONS FOR BMP BINDING PROTEIN - The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired. | 11-14-2013 |
20130316949 | Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members - The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent. | 11-28-2013 |
20140005111 | INJECTABLE DELIVERY SYSTEM FOR HEPARAN-BINDING GROWTH FACTORS | 01-02-2014 |
20140051632 | Sustained-Release Formulations Comprising Crystals, Macromolecular Gels, and Particulate Suspensions of Biologic Agents - The present invention is directed to sustained release formulations of biologic agents which permit persistent bioavailability. Preferred biologic agents include bone morphogenetic proteins. Diseases susceptible to amelioration and/or treatment with the formulations of the present invention include skeletal tissue diseases such as, but not limited to, osteoarthritis and other osteochondral diseases. The sustained release formulations of the present invention are especially suitable for treatment of minimally-vascularized or non-vascularized tissue sites such as, but not limited to, intra joint, interarticular, or intraminiscal sites. | 02-20-2014 |
20140100161 | System and Method for Multiphasic Release of Growth Factors - A system for multiphasic delivery of at least one growth factor at a treatment site comprises a delivery vehicle for releasing at least one growth factor in an initial release profile and a carrier for releasing at least one growth factor in a sustained release profile. The initial release profile releases at least one growth factor over a period of hours to days, wherein the growth factor is released in a large amount initially, with the remainder being released in progressively lower amounts. The sustained release profile releases at least one growth factor over a period of days to weeks, wherein the growth factor is released at a generally constant amount over such period. The system of the invention is particularly suited for applications on bioimplants. The invention also comprises methods and kits for multiphasic delivery of at least one growth factor. | 04-10-2014 |
20140148387 | FREEZE-DRIED RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 PREPARATION - The present invention provides a freeze-dried preparation obtained by dissolving an active type human bone morphogenetic protein-2 homodimer added with an alanine residue to the N-terminus in a strong acid solution and freeze-drying the solution, a production method of the preparation, and a kit for regeneration and treatment of bone, which contains the preparation. | 05-29-2014 |
20140171367 | Polymer Hydrogels For In Vivo Applications And Methods For Using And Preparing Same - Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated. | 06-19-2014 |
20140187486 | Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease - The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent. | 07-03-2014 |
20140200182 | METHODS OF ADMINISTERING BONE MORPHOGENETIC PROTEIN COMPOSITIONS - The present invention relates to compositions of bone morphogenetic proteins, particularly solid and liquid formulations of such proteins comprising one or more stabilizing excipients. The invention further provides methods of producing the compositions, kits comprising the compositions and methods of using the compositions in the treatment of diseases of skeletal and non-skeletal tissues. | 07-17-2014 |
20140315807 | Treatment and Prevention of Bone Loss Using Resolvins - The invention provides new methods for inducing or promoting bone growth and/or for reducing or preventing bone deterioration in a mammal subject. The inventive methods generally comprise administering to the subject an effective amount of a resolving. In particular, the inventive methods may be useful for treating or preventing conditions associated with bone degradation, deterioration or degeneration such as periodontal disease, osteoarthritis, and metastatic bone disease and osteolytic bone disease. Pharmaceutical compositions and kits comprising at least one resolving are also provided that can be used to performed the inventive methods. | 10-23-2014 |
20140336114 | Buffers for Controlling the pH of Bone Morphogenetic Proteins - The present invention provides formulations of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins that are pH stabilized. In particular, the present invention relates to the observation that certain buffers enhance the stability of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins. In particular, disclosed herein are liquid and lyophilized formulations prepared with a glycylglycine and tartaric acid buffers to stabilize the pH of the formulation. | 11-13-2014 |
20150011472 | MALLEABLE MULTI-COMPONENT IMPLANTS AND MATERIALS THEREFOR - Described are implantable, malleable medical materials comprising mineral particles, insoluble collagen fibers, and a gel-forming polysaccharide component and/or another added gel-former. The malleable medical materials can be used treat bone or other tissue defects in patients, including in conjunction with biologically active factors such as osteogenic proteins. Also described are methods and materials that can be used to prepare the malleable medical materials. | 01-08-2015 |
20150045297 | GROWTH DIFFERENTIATION FACTOR (GDF) FOR TREATMENT OF DIASTOLIC HEART FAILURE - The technology described herein relates to treatments for, e.g., diastolic heart failure, cardiac hypertrophy, and related conditions. | 02-12-2015 |
20150051148 | HYDROGEL SYSTEM COMPRISING SPATIALLY SEPARATED BIOACTIVE POLYPEPTIDES - The present invention provides a multi-compartment hydrogel, and a sulfated polysaccharide and at least two bioactive polypeptides capable of binding said sulfated polysaccharide, for use in repair or regeneration of a damaged tissue in a mammal. Also provided is a method for constructing the multi-compartment hydrogel. The present invention also provides a method for the repair or regeneration of a damaged tissue in a mammal, and a kit for constructing a multi-compartment hydrogel. | 02-19-2015 |
20150057222 | METHODS OF TREATING CARTILAGE DEFECTS USING A SOLUBLE MORPHOGENIC PROTEIN COMPLEX - The present invention provides methods of repairing and regenerating cartilage tissue using a soluble morphogenic protein complex comprising (a) a morphogenic protein; and (b) a morphogenic protein pro region isolated from a morphogenic protein, or a conservative substitution variant or a fragment of said pro region, wherein said pro region or variant or fragment is noncovalently linked to the morphogenic protein, and wherein said complex is more soluble in an aqueous solvent than said morphogenic protein alone. | 02-26-2015 |
20150080303 | DEVICE HAVING OSTEOINDUCTIVE AND OSTEOCONDUCTIVE PROPERTIES - The present invention relates to a device having osteoinductive and osteoconductive properties in vivo comprising a carrier containing calcium phosphate and an osteoinductive protein, wherein the carrier is homogenously coated with the protein. Moreover, the present invention relates to a method for the production of a device having osteoinductive and osteoconductive properties in vivo. The invention encompasses a pharmaceutical composition comprising the device of the invention or a device which is obtainable by the method of the invention and relates to the use of the device for the preparation of a pharmaceutical composition to be used for bone augmentation, for treating bone defects, for treating degenerative and traumatic disc disease, for treating bone dehiscence or to be used for sinus floor elevation. Finally, the invention relates to a kit comprising the device of the invention or a device which is obtainable by the method of the invention. | 03-19-2015 |
20150141333 | KERATIN BIOCERAMIC COMPOSITIONS - A malleable bone graft composition is described. The composition comprises: (a) keratose; (b) particulate filler; (c) antibiotic; and (d) water. The invention may be provided in sterile form in an container, and optionally lyophilized. Methods of treating a fracture with such compositions are also described. | 05-21-2015 |
20150148292 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO - The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair, and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as 2-(2-Methoxybenzylidene)-1-indan-one; N-(4-arsonophenyl)glycine; 1,2-Benzenedicarboxylic acid, 1-(1-methylheptyl)ester; (4′-hydroxybiphenyl-4-yl) (phenyl)methanone; 2,2-dimethylchroman-6-carboxylic acid, (4,7-dihydroxy-8-methyl-2-oxo-2H-chromen-3-yl)amide; Ethyl 2-((4-chlorophenyl)thio)-1,3-benzothiazol-6-yl carbamate; Ethyl (2-(azepan-1-yl)benzo[d]thiazol-6-yl) carbamate; Porfiromycin; 1,3-benzodioxol-5-yl-[4-(3,4,5-trimethoxybenzoyl)-3-furyl]methanone; Tricinolone acetophenonide; 2,4-bis(3,4-dimethoxyphenyl)-4H-pyrano[3,2-c]chromen-5-one; Methyl 5-fluoro-4-methoxy-2,6-dioxohexahydro-5-pyrimidine carboxylate; 5-(naphthalen-1-yl)-1-phenyl-1h-tetrazole; 5-(2-phenylquinolin-4-yl)-1,3,4-oxadiazol-2-ol; N-[2,4,5-trimethyl-4-(trichloromethyl)cyclohexa-2,5-dien-1-ylidene]hydroxylamine; 4-benzoyl-3,4-dihydro-Benzo[f]quinoline-3-carbonitrile; 2-nitro-3-phenylspiro[cyclopropane-1,9′-fluorene]; 3-[4-(furan-2-ylmethyl)-5-sulfanylidene-1,2,4-dithiazolidin-3-ylidene]-1,1-dimethyl-thiourea; (6-acetamido-7-methyl-5,8-dioxo-2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazol-3-yl)2-methoxyacetate; 5-Iodo-1H-indole-2,3-dione; 4,5-dihydro-1,2,9,10-tetramethoxy dibenzo[de,g]quinoline-6-carboxylic acid, ethyl ester; [2,6-bis(2,4-dimethylphenyl)-4-(2-methoxyacetyl)oxy-phenyl]2-methoxyacetate; 5,11-dimethyl-2-(2-piperidin-1-ylethyl)-6H-pyrido[4,3-b]carbazol-2-ium-9-ol; 2-[3-[[4-[(3-nitroacridin-9-yl)amino]phenyl]sulfamoyl]propyl]guanidine; 1-[[2-(dimethylamino)ethyl]amino]-7-hydroxy-4-methyl-9H-thioxanthen-9-one; 5-amino-1H-1,2,4-triazole-3-carboxylic acid, methyl ester; methyl N-cyano-N′-prop-2-en-1-ylcarbamimidothioate; 5,7-dinitro-8-quinolinol; 5-nitrosoquinolin-8-ol; Cantharidin; 1,7-Diaminoacridine; 3-Methyl-3-(1-naphthyl)-2-benzofuran-1(3H)-one; Dichlorolapachol; Lycobetaine; 6-(1-aziridinyl)-2,3-dihydro-3-(propionyl)-7-methyl-1H-Pyrrolo[1,8]-dione; 4-Nitroestrone 3-methyl ether; 5,11-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide hydrochloride; 5-Methoxysterigmatocysin; (6-acetamido-7-methyl-5,8-dioxo-2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazol-3-yl)2-methoxyacetate; Horminon; 7′,8′-dimethyl-2′-oxo-4′,4a′,6a′,7′-tetrahydro-2′H-spiro[oxirane-2,1′-pentaleno[1,6a-c]pyran]-5′-carboxylate; Nybomycin acetate; 5H-[1,6]indeno[1,2-c]isoquinoline-5,12-dione; 2,3-dimethoxy-6-methyl-Nitidine; Iproplatin; 3-[(deoxyhexosyl)oxy]-2-(3,4-di-hydroxyphenyl)-6,8-dihdroxy-4H-1-Benzopyran-4-one; 2-O-benzyl 8-O-methyl 3-(4-methylphenyl)sulfonyl-4,5-dioxo-6H-pyrrolo[3,2-e]indole-2,8-dicarboxylate; 6-bromo-5,8-dihydroxy-7-[4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl]naphthalene-1,4-dione; 5-methylbenzo[c]phenanthridin-5-ium-2,3,8,9-tetrol; (6-acetyl-4-oxo-1,3-diphenyl-2-sulfanylidenethieno[2,3-d]pyrimidin-5-yl)-2,4-dichlorobenzoate; N—[C-[4-[bis(2-cyanoethyl)amino]-2-methylphenyl]-N-(4-methylanilino)carbonimidoyl]imino-4-methylbenzamide; Gelcohol; Curcumin; Tirandamycin; Noscapine; Aristolochic acid; Himbacine; Fumagillin; Fumitremorgin C; Physalin B; derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. In certain embodiments, compounds disclosed herein are useful for managing obesity and diabetes or other metabolic syndromes by modulation of brown fat. | 05-28-2015 |
20150306179 | CONCENTRATED PROTEIN PREPARATIONS OF BONE MORPHOGENETIC PROTEINS AND METHODS OF USE THEREOF - Disclosed herein are heretofore undescribed preparations of highly concentrated, solubilized proteins, such as but not limited to, Bone Morphogenetic Proteins. Such protein preparations can be formulated in an aqueous carrier at protein concentrations in excess of 10 mg/ml when using the methods of manufacture taught herein. Such methods yield stable protein preparations in either solubilized or lyophilized form. The protein preparations of the present invention are particularly beneficial when administered either locally or systemically, in part, because low administration volumes can be accomplished. This is especially important for local treatment of certain anatomic locations such as, for example, the synovial fluid of a joint when treating osteoarthritis with BMP-7 or the intradiscal space when treating degenerative disc disease with BMP-7. | 10-29-2015 |
20150307588 | ENDOGLIN POLYPEPTIDES AND USES THEREOF - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. | 10-29-2015 |
20150337025 | USE OF FUSION PROTEIN - Disclosed is the use of a fusion protein in drugs for stimulating differentiation of bone marrow mesenchymal stem cells to hematopoietic stem/progenitor cells, or drugs for proliferation of granulocyte hematopoietic progenitor cells. The fusion protein has a sequence as shown in SEQ ID NO: 2 or SEQ ID NO: 4. The drugs can be used for the prevention and/or treatment of (i) hematopoietic dysfunction caused by chemotherapy, (ii) hematopoietic dysfunction caused by radiotherapy, or (iii) leukopenia. | 11-26-2015 |
20150366880 | COMPOSITIONS AND METHODS FOR TREATING BONE DISEASES AND BROKEN BONES - Disclosed herein are methods of promoting osteogenesis in a subject, comprising administering a composition comprising a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA). Also disclosed herein are methods of promoting osteogenesis in a subject in need of such promotion, comprising administering a composition comprising a therapeutically effective amount of at least one CSA. Additionally, disclosed herein are compounds and compositions comprising at least one CSA, or a pharmaceutically acceptable salt thereof, for use in the treatment of bone disease or the treatment of broken bones. Kits comprising such compositions and instructions on such methods are also contemplated herein. | 12-24-2015 |
20160000860 | ENHANCEMENT OF BMP RETENTION - The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical comorbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders. | 01-07-2016 |
20160052984 | OSTEOGENIC PROTEINS - The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics. | 02-25-2016 |
20160058867 | CROSSLINKED CHITOSAN-LACTIDE HYDROGELS - Aspects of the invention include crosslinked copolymer hydrogel compositions. Crosslinked copolymer hydrogel compositions according to certain embodiments include a copolymer of chitosan and a polyester and a hydrolysable crosslinker. In certain embodiments, crosslinked hydrogels further include fibrinogen. The subject invention also describes compositions having crosslinked copolymer hydrogels with one or more absorbed bioactive agents. Methods for preparing and using the crosslinked copolymer hydrogels of the invention are also described. | 03-03-2016 |
20160097100 | GENETIC TEST TO PREDICT PATIENT RESPONSE TO BONE MORPHOGENETIC PROTEIN IN ARTHRODESIS - The present invention provides a method of predicting an increased likelihood of a complication associated with administration of a bone morphogenetic protein (BMP) to a subject in need of a spinal fusion surgery by detecting single nucleotide polymorphisms (SNPs) in the subject. Also provided are methods of treatment with a BMP based on the presence or absence of SNPs and kits for use in detecting the SNPs. | 04-07-2016 |
20160143984 | CHEMICAL REPROGRAMMING OF HUMAN GLIAL CELLS INTO NEURONS FOR BRAIN AND SPINAL CORD REPAIR - Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-β), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and γ-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG, purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations. | 05-26-2016 |
20160376334 | POSITIVE MODULATOR OF BONE MORPHOGENIC PROTEIN-2 - Compounds of the present invention of formula I and formula II are disclosed in the specification and wherein the compounds are modulators of Bone Morphogenic Protein activity. Compounds are synthetic peptides having a non-growth factor heparin binding region, a linker, and sequences that bind specifically to a receptor for Bone Morphogenic Protein. Uses of compounds of the present invention in the treatment of bone lesions, degenerative joint disease and to enhance bone formation are disclosed. | 12-29-2016 |